CDC5L: A Promising Drug Target and Biomarker for Cancer Treatment
CDC5L: A Promising Drug Target and Biomarker for Cancer Treatment
Introduction
Cancer is a leading cause of morbidity and mortality worldwide, affecting millions of individuals across the globe. The rapid proliferation and uncontrolled growth of cancer cells contribute to their emergence as a leading cause of mortality. The conventional treatment options for cancer have limited their effectiveness, leading to a growing need for new and innovative approaches. In recent years, there has been an increasing interest in the research of CDC5L (CDC5 cell division cycle 5-like), a protein that plays a critical role in cell division and has been identified as a potential drug target and biomarker for cancer treatment.
CDC5L: The Character of CDC5L
CDC5L is a protein that belongs to the family of cyclins, which are essential for the regulation of cell division. It is a 21-kDa protein that is expressed in various tissues, including the brain, pancreas, and gastrointestinal tract. CDC5L is responsible for activating the G1 phase of the cell cycle, which is the stage of cell growth and preparation for cell division.
CDC5L functions as a negative regulator of the G1/S transition, which is the critical point in the cell cycle where the cell prepares for cell division. The G1/S transition is a critical step in the cell cycle where the cell grows, replicates its DNA, and prepares for the subsequent phase of cell growth. However, the G1/S transition is also the stage where the cell is most susceptible to external factors, such as stress, DNA damage, and hormonal changes.
CDC5L plays a crucial role in regulating the G1/S transition by inhibiting the activity of the G1-specific factor, p21 (CDK4), which promotes the G1 phase and the S phase. p21 is a well-known protein that is expressed in various tissues and is involved in cell growth, differentiation, and the regulation of cell cycle progression. By inhibiting the activity of p21, CDC5L ensures that the cell stays in the G1 phase for a longer period, allowing it to carry out essential cellular processes before entering the S phase.
CDC5L as a Drug Target
The potential of CDC5L as a drug target is based on its critical role in the regulation of cell cycle progression and its involvement in various cellular processes. Several studies have demonstrated that targeting CDC5L can result in significant improvements in cancer treatment outcomes.
One of the most significant findings is the ability of small molecule inhibitors to target CDC5L and inhibit its activity. Several studies have shown that inhibitors of CDC5L, such as 纬-secretase inhibitors, can significantly reduce the growth of cancer cells, including human breast cancer cells. These inhibitors work by inhibiting the activity of 纬-secretase, a protein that is involved in the delivery of newly synthesized proteins to the endoplasmic reticulum, which is a critical step in protein folding and translation.
Another approach to targeting CDC5L is the use of RNA interference (RNAi) technology. RNAi is a technique that involves the use of small interfering RNA (siRNA) to knock down the expression of specific genes. Several studies have shown that RNAi can be used to specifically knock down the expression of CDC5L and result in the inhibition of its activity.
CDC5L as a Biomarker
In addition to its potential as a drug target, CDC5L has also been identified as a potential biomarker for cancer treatment. The G1/S transition is a critical point in the
Protein Name: Cell Division Cycle 5 Like
Functions: DNA-binding protein involved in cell cycle control. May act as a transcription activator. Plays role in pre-mRNA splicing as core component of precatalytic, catalytic and postcatalytic spliceosomal complexes (PubMed:11991638, PubMed:20176811, PubMed:28502770, PubMed:28076346, PubMed:29361316, PubMed:29360106, PubMed:29301961, PubMed:30728453, PubMed:30705154). Component of the PRP19-CDC5L complex that forms an integral part of the spliceosome and is required for activating pre-mRNA splicing. The PRP19-CDC5L complex may also play a role in the response to DNA damage (DDR) (PubMed:20176811). As a component of the minor spliceosome, involved in the splicing of U12-type introns in pre-mRNAs (Probable)
The "CDC5L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDC5L comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19 | CDK2 | CDK20 | CDK2AP1 | CDK2AP2 | CDK2AP2P2 | CDK2AP2P3 | CDK3 | CDK4 | CDK5 | CDK5R1 | CDK5R2 | CDK5RAP1 | CDK5RAP2 | CDK5RAP3 | CDK6 | CDK6-AS1 | CDK7 | CDK8 | CDK9 | CDKAL1 | CDKL1 | CDKL2 | CDKL3 | CDKL4 | CDKL5 | CDKN1A | CDKN1B | CDKN1C | CDKN2A | CDKN2A-DT | CDKN2AIP | CDKN2AIPNL | CDKN2AIPNLP1 | CDKN2B | CDKN2B-AS1 | CDKN2C | CDKN2D | CDKN3 | CDNF | CDO1
